"id","studyRationale","studyVersion","studyAcronym","studyTitle","uuid:ID"
"StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","H2Q-MC-LZZT","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","d4b6f5c5-9e97-44fd-a8ba-249f16038ff3"
